Hematology Disease Topics & Pathways:
Clinical Trials, Sickle Cell Disease, Access To Care, Epidemiology, Sickle Cell Trait, Workforce, Health Outcomes Research, Health Disparities Research, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Hemoglobinopathies, Patient-Reported Outcomes, Diseases, Real World Evidence, Disparities, Registries, Racial Inequities, Diversity, Equity, and Inclusion (DEI), Racism, Clinical Practice (e.g. Guidelines, Health Outcomes and Services, and Survivorship, Value; etc.)
Sickle cell disease (SCD) affects 100,000 people living in the US and 250-300,000 births annually worldwide. Despite its frequency, the natural history of SCD and its complications remain poorly understood. Over the past decade, clinical research has led to much progress in disease management, identifying novel therapeutic targets and FDA approval of two new therapies, crizanlizumab and voxelotor, in the fall of 2019. For the past 18 months, SCD research has been over-shadowed by the COVID-19 pandemic and many hematologists not directly involved in this work may not be up to date on recent findings. This compounds the known health care disparities in this field. We plan to highlight six poster abstracts focused on clinical research in SCD to review critically and discuss with the authors SCD to increase dissemination of their data. The organizers of this poster walk bring expertise in adult and pediatric hematology and pulmonary/critical care to the discussion and represent leadership from two major sickle cell centers in the United States.
The following abstracts will be featured in this session:
The Burden of Atrial Fibrillation in Sickle Cell Disease, Chinonso Ukeje
Cognitive Profile of Adults with Sickle Cell Disease - Cluster Analysis, Maryline Couette